301 related articles for article (PubMed ID: 23526298)
1. GPR109A and vascular inflammation.
Chai JT; Digby JE; Choudhury RP
Curr Atheroscler Rep; 2013 May; 15(5):325. PubMed ID: 23526298
[TBL] [Abstract][Full Text] [Related]
2. Nicotinic acid (niacin) receptor agonists: will they be useful therapeutic agents?
Kamanna VS; Kashyap ML
Am J Cardiol; 2007 Dec; 100(11 A):S53-61. PubMed ID: 18047854
[TBL] [Abstract][Full Text] [Related]
3. Flushing out the role of GPR109A (HM74A) in the clinical efficacy of nicotinic acid.
Pike NB
J Clin Invest; 2005 Dec; 115(12):3400-3. PubMed ID: 16322787
[TBL] [Abstract][Full Text] [Related]
4. Differential tissue and ligand-dependent signaling of GPR109A receptor: implications for anti-atherosclerotic therapeutic potential.
Gaidarov I; Chen X; Anthony T; Maciejewski-Lenoir D; Liaw C; Unett DJ
Cell Signal; 2013 Oct; 25(10):2003-16. PubMed ID: 23770183
[TBL] [Abstract][Full Text] [Related]
5. Recent advances in niacin and lipid metabolism.
Kamanna VS; Ganji SH; Kashyap ML
Curr Opin Lipidol; 2013 Jun; 24(3):239-45. PubMed ID: 23619367
[TBL] [Abstract][Full Text] [Related]
6. Niacin inhibits skin dendritic cell mobilization in a GPR109A independent manner but has no impact on monocyte trafficking in atherosclerosis.
Ingersoll MA; Potteaux S; Alvarez D; Hutchison SB; van Rooijen N; Randolph GJ
Immunobiology; 2012 May; 217(5):548-57. PubMed ID: 21798616
[TBL] [Abstract][Full Text] [Related]
7. Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppression.
Lauring B; Taggart AK; Tata JR; Dunbar R; Caro L; Cheng K; Chin J; Colletti SL; Cote J; Khalilieh S; Liu J; Luo WL; Maclean AA; Peterson LB; Polis AB; Sirah W; Wu TJ; Liu X; Jin L; Wu K; Boatman PD; Semple G; Behan DP; Connolly DT; Lai E; Wagner JA; Wright SD; Cuffie C; Mitchel YB; Rader DJ; Paolini JF; Waters MG; Plump A
Sci Transl Med; 2012 Aug; 4(148):148ra115. PubMed ID: 22914621
[TBL] [Abstract][Full Text] [Related]
8. GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing.
Benyó Z; Gille A; Kero J; Csiky M; Suchánková MC; Nüsing RM; Moers A; Pfeffer K; Offermanns S
J Clin Invest; 2005 Dec; 115(12):3634-40. PubMed ID: 16322797
[TBL] [Abstract][Full Text] [Related]
9. Effects of niacin on atherosclerosis and vascular function.
Ruparelia N; Digby JE; Choudhury RP
Curr Opin Cardiol; 2011 Jan; 26(1):66-70. PubMed ID: 21045681
[TBL] [Abstract][Full Text] [Related]
10. Niacin mitigates blood-brain barrier tight junctional proteins dysregulation and cerebral inflammation in ketamine rat model of psychosis: Role of GPR109A receptor.
Ibrahim WW; Sayed RH; Kandil EA; Wadie W
Prog Neuropsychopharmacol Biol Psychiatry; 2022 Dec; 119():110583. PubMed ID: 35690118
[TBL] [Abstract][Full Text] [Related]
11. Future of GPR109A agonists in the treatment of dyslipidaemia.
Wanders D; Judd RL
Diabetes Obes Metab; 2011 Aug; 13(8):685-91. PubMed ID: 21418500
[TBL] [Abstract][Full Text] [Related]
12. Pleiotropic effects of niacin: Current possibilities for its clinical use.
Zeman M; Vecka M; Perlík F; Staňková B; Hromádka R; Tvrzická E; Širc J; Hrib J; Žák A
Acta Pharm; 2016 Dec; 66(4):449-469. PubMed ID: 27749252
[TBL] [Abstract][Full Text] [Related]
13. Modulation of HDL metabolism by the niacin receptor GPR109A in mouse hepatocytes.
Li X; Millar JS; Brownell N; Briand F; Rader DJ
Biochem Pharmacol; 2010 Nov; 80(9):1450-7. PubMed ID: 20655299
[TBL] [Abstract][Full Text] [Related]
14. The psoriasis drug monomethylfumarate is a potent nicotinic acid receptor agonist.
Tang H; Lu JY; Zheng X; Yang Y; Reagan JD
Biochem Biophys Res Commun; 2008 Oct; 375(4):562-5. PubMed ID: 18722346
[TBL] [Abstract][Full Text] [Related]
15. Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells.
Lukasova M; Malaval C; Gille A; Kero J; Offermanns S
J Clin Invest; 2011 Mar; 121(3):1163-73. PubMed ID: 21317532
[TBL] [Abstract][Full Text] [Related]
16. Nicotinic acid (niacin): new lipid-independent mechanisms of action and therapeutic potentials.
Lukasova M; Hanson J; Tunaru S; Offermanns S
Trends Pharmacol Sci; 2011 Dec; 32(12):700-7. PubMed ID: 21944259
[TBL] [Abstract][Full Text] [Related]
17. The niacin/butyrate receptor GPR109A suppresses mammary tumorigenesis by inhibiting cell survival.
Elangovan S; Pathania R; Ramachandran S; Ananth S; Padia RN; Lan L; Singh N; Martin PM; Hawthorn L; Prasad PD; Ganapathy V; Thangaraju M
Cancer Res; 2014 Feb; 74(4):1166-78. PubMed ID: 24371223
[TBL] [Abstract][Full Text] [Related]
18. Discovery of 4-(phenyl)thio-1H-pyrazole derivatives as agonists of GPR109A, a high affinity niacin receptor.
Kim HY; Jadhav VB; Jeong DY; Park WK; Song JH; Lee S; Cho H
Arch Pharm Res; 2015 Jun; 38(6):1019-32. PubMed ID: 25599616
[TBL] [Abstract][Full Text] [Related]
19. Niacin Alternatives for Dyslipidemia: Fool's Gold or Gold Mine? Part II: Novel Niacin Mimetics.
Goel H; Dunbar RL
Curr Atheroscler Rep; 2016 Apr; 18(4):17. PubMed ID: 26932224
[TBL] [Abstract][Full Text] [Related]
20. Niacin: a re-emerging pharmaceutical for the treatment of dyslipidaemia.
Vosper H
Br J Pharmacol; 2009 Sep; 158(2):429-41. PubMed ID: 19627285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
